EWING, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that U.S. Patent number 8,518,437 was issued by the United States Patent and Trademark Office on August 27, 2013. The new patent, “Lipid Carrier Compositions with Enhanced Blood Stability,” covers Celator’s proprietary low-cholesterol liposome compositions utilized in the Company's two clinical stage products, CPX-351 and CPX-1, which are based on the company’s innovative technology platform called CombiPlex. With the Patent Term Adjustment, this patent provides protection until June 2026.
“We look forward to further exploring the full potential of the technology and how it could possibly be applied to a wide range of drug classes and drug combinations.”
“The low-cholesterol liposome technology has been instrumental in achieving the excellent biological and pharmaceutical stability features exhibited by CPX-351 and CPX-1, and has no doubt contributed to the promising clinical activity observed to date for these products,” said Lawrence Mayer, Ph.D., president and chief scientific officer at Celator. “We look forward to further exploring the full potential of the technology and how it could possibly be applied to a wide range of drug classes and drug combinations.”
Historically, most liposomal drug delivery nanoparticles have incorporated equal amounts of phospholipids and cholesterol, but Celator scientists discovered that very unique properties arise when the cholesterol content ranges from five to twenty percent. In this range, the release of drugs from the liposome can be controlled to maintain the desired molar ratio. The liposomes also exhibit extended blood circulation times without the use of surface-grafted polymers and have physically robust compositions that are resistant to damage from freezing and freeze-drying.
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company’s proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia, and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:cisplatin), and the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory. For more information, please visit the company’s website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the intellectual property protection that may be afforded by any patents relating to our technology and our expectations regarding our development plans for CPX-351 and our drug candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator’s Form 10-K for the year ended December 31, 2012 and other filings by the company with the U.S. Securities and Exchange Commission.